New biosimilar aims to offer affordable alternative to keytruda for lung cancer
Disease control
Completed
This study tested whether a new biosimilar drug, GME751, works as well as the standard treatment Keytruda for people with advanced non-squamous lung cancer that has spread. About 218 adults who had not received prior treatment took part. The goal was to see if the biosimilar coul…
Phase: PHASE3 • Sponsor: Sandoz • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC